precision medicine for ophthalmology

Character is a precision medicine company that is unlocking the patterns of progressive polygenic diseases, with an initial focus on macular degeneration. Our mission is to use human genetics to understand what drives disease progression so we can discover and develop targeted therapies to more effectively treat patients - many of whom lack any treatment options today.

polygenic diseases
are not monolithic

For the last century, many diseases have been treated as monolithic and homogenous with very little granularity.

we're unlocking the
patterns of disease

The truth, as we see in our work every day, is that diseases are as diverse as the patients they impact. That’s why we are building world-class clinical genomic databases in focused disease areas to characterize the diversity of biological pathways driving disease progression and to develop pathway-specific targeted medicines.

age-related diseases
are not monolithic

For the last century, most diseases have been treated as monolithic and homogenous with very little granularity.

we're unlocking the
patterns of disease

The truth, as we see in our work every day, is that diseases are as diverse as the patients they impact. That’s why we are building world-class clinical genomic databases to characterize the diversity of biological pathways driving disease progression and to develop pathway-specific precision medicine.

revealing the nuances in
disease progression

Character is working to transform the trial-and-failure paradigm of drug development by identifying the right drug targets for the right patients - bringing better medicines more quickly to patients who need them. Character partners with patients, providers, payers, and scientists to create large, deeply phenotyped patient groups to enable clinical genomic research. Our approach integrates genomics, longitudinal clinical data, and machine learning to drive drug discovery and patient biomarker development.

Patient
Network
Longitudinal
disease progression
Full-stack, curated clinical database of imaging, EMR, claims, and lab data
Integrated
multi-omics
Genomics and other omics to characterize diseases at the molecular level
Machine learning
phenotyping
Advanced machine learning to quantify phenotypes of disease progression
In-house drug and biomarker pipeline
Novel therapeutics
and patient biomarkers

the character precision medicine platform

Our clinical genomic and deep phenotyping platform powers drug discovery and development by enabling prioritization of drug pathways and targets associated with disease progression, clinical trial design optimization with patient stratification, and trial execution with our existing provider and patient network.

Hover over left image for more.

Tap the image above for more.

Volumetric OCT: Dry age-related macular degeneration
Fundus autofluorescence: Dry age-related macular degeneration

our programs

Research
Pre-clinical
Clinical
Pipeline
Research
Pre-clinical
Clinical

1. Complement inhibitor - Geographic Atrophy (GA)

2. Lipid modulator - Intermediate Age-related Macular Degeneration

3. Glaucoma

4. Announcing soon

let's solve polygenic diseases together

Provider Partnerships

By working with ophthalmologists and other treating physicians, we are determined to understand how diseases behave in real life and tackle the largest unmet needs.

Patient
Research

As a patient, you have an opportunity to contribute to research that could deliver better treatments for you and others like you in the future.

Industry Partnerships

As pioneers of human genetics-based drug discovery and development in ophthalmology, we are harnessing the power of integrated patient data, genomics and machine learning to develop transformative medicines.